RT Journal Article
SR Electronic
T1 Relative vaccine effectiveness of a CoronaVac booster dose in preventing symptomatic SARS-CoV-2 infection among healthcare workers during an Omicron period in Azerbaijan, January–August 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.20.23297300
DO 10.1101/2023.10.20.23297300
A1 Finci, Iris
A1 Rojas Castro, Madelyn Yiseth
A1 Seyidov, Nabil
A1 Mehdiyev, Samir
A1 McKnight, C. Jason
A1 Mühlemann, Barbara
A1 Drosten, Christian
A1 Duca, Lindsey
A1 Pebody, Richard
A1 Kissling, Esther
A1 Katz, Mark A.
A1 Hagverdiyev, Gahraman
YR 2023
UL http://medrxiv.org/content/early/2023/10/25/2023.10.20.23297300.abstract
AB Among Azerbaijani healthcare workers (HCWs), compared to primary vaccine series, CoronaVac booster relative vaccine effectiveness was 60% (95% CI:25–79) and 79% (95% CI:44–92) against symptomatic and medically attended illness, respectively, during an Omicron BA.1/BA.2 period. Our results support timely CoronaVac booster uptake among Azerbaijani HCWs to reduce morbidity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by The Task Force for Global Health and World Health Organisation Regional Office for Europe.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the WHO Research Ethics Review Committee (protocol: CERC.0097C) and the Ethics Committee of Azerbaijan State Academy of Physical Culture and Sport (March 3, 2021; Protocol #3/21). All participants provided informed, written consent. The study is registered in the clinicaltrails.gov registry (NCT050694).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are not publicly available due to privacy or ethical restrictions. The authors do not have consent from study participants to share the data.